Miltenyi Biotec B.v. Co., Kg

St. Jude Children's Research Hospital

Rafijul Bari

Wing Leung

Markus Granzin

Andrzej Dzionek

Volker Huppert

Martin Meyer

Nina Moker

Nina MÖKER

The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.

Method for NK cell transduction

The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Chimeric antigen receptor specific for BDCA2 antigen

A nucleic acid construct and mammalian cell harboring nucleic acids encoding an anti-CD7 chimeric antigen receptor are provided. Methods for treating cancer, in particular a hematologic cancer, using the nucleic acid construct or mammalian cell are also described.

Anti-CD7 chimeric antigen receptor and method of use thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Rafijul Bari